Abstract:Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely, elimination, homeostasis and escape, tumor cells are no longer restricted by immune surveillance and thus develop into clinical tumors. The mechanisms of immune escape include abnormalities in antitumor-associated immune cells, selection for immune resistance to tumor cells, impaired transport of T cells, and the formation of an immunosuppressive tumor microenvironment. A population of distinct immature myeloid cells, myeloid-derived suppressor cells (MDSCs), mediate immune escape primarily by exerting immunosuppressive effects and participating in the constitution of an immunosuppressive microtumor environment. Clinical trials have found that the levels of MDSCs in the peripheral blood of cancer patients are strongly correlated with tumor stage, metastasis and prognosis. Moreover, animal experiments have confirmed that elimination of MDSCs inhibits tumor growth and metastasis to some extent. Therefore, MDSCs may become the target of immunotherapy for many cancers, and eliminating MDSCs can help improve the response rate to cancer treatment and patient survival. However, a clear definition of MDSCs and the specific mechanism involved in immune escape are lacking. In this paper, we review the role of the MDSCs population in tumor development and the mechanisms involved in immune escape in different tumor contexts. In addition, we discuss the use of these cells as targets for tumor immunotherapy. This review not only contributes to a systematic and comprehensive understanding of the essential role of MDSCs in immune system reactions against tumors but also provides information to guide the development of cancer therapies targeting MDSCs.

Research advance in Tumor-associated dendritic cells,macrophages,and myeloid derived suppressive cells

Advances in tumor-associated immunosuppressive cells and mechanism of immune escape

Suppressive Mechanisms of Tumor Associated Immunosuppressive Cells in Immune Escape

Tumor Cells Related Research Progress of Immune Suppression

Effect of Tumor Derived Factors on Tumor Associated Immnnosuppressive Cells

Disturbance of Differentiation and Maturation of Dendritic Cells and Tumor Escape

Research advance of myeloid-derived suppressor cells on bionomics and immunosuppressive action and related immunotherapy

Tumor Cells Evade Immunosurveillance by Suppressing Dendritic Cell Function

Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Myeloid-derived Suppressor Cells:Mechanisms of Immune Suppression and Advancements in Anti-Tumor Immunity Therapy

Recent Progress on MDSCs and Tumor Immune Tolerance

Suppressive Myeloid Cells Shape the Tumor Immune Microenvironment

Impaired function of dendritic cells within the tumor microenvironment

Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment

Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in cancer

Immunosuppressive Cells in Cancer: Mechanisms and Potential Therapeutic Targets